Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Onward Medical N.V.

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. 

ONWARD Medical has received nine Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed its first-in-human use of the ARC-IM neurostimulator in May 2022. 

ONWARD Medical is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). 

ONWARD

🎉 Congratulations to our Vice President, Clinical, Regulatory, & Quality, Dr. Erika Ross Ellison, for her recent election as President of the Institute of Electrical and Electronics Engineers IEEE Engineering in Medicine and Biology Society (EMBS), the world’s largest international society of biomedical engineers. 
 
We proudly celebrate Erika’s historic achievement. Her election marks the first time in the 72-year history of IEEE EMBS that a leader from industry will serve in this volunteer position. Erika will be the 7th woman in the society’s history to lead the organization. 
 
IEEE EMBS is driven by a mission to create innovations in healthcare technology for the benefit of all humanity. The group’s 12,000 members span 97 countries and include #researchers, #educators, #engineers and #clinicans. Their areas of expertise run wide and deep, including medical technology, #bioinformatics, #biotechnology, #robots. Many are also focused on the translation of science to clinical practice.  
 
We also celebrate this moment as an opportunity to further collaborate across the intersection of health and technology. As a company dedicated to developing groundbreaking solutions to serve the spinal cord injury (SCI) Community, having visibility and access to the most cutting-edge resources and talent is a true honor.  
 
Way to go, Erika! 🎉 
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

#EmpoweringMovement #SCI

Looking forward to participating in BioCapital Europe in Amsterdam TODAY! 

The event, one of Europe’s leading life sciences investor conferences, is organized by venture capital fund EQT Group, an investor in our company.

During the conference, CEO Dave Marver will present and participate in 1:1 and group meetings with investors to discuss the Company’s leadership in neuroscience, including the use of our investigational ONWARD ARC-IM® Therapy paired with brain-computer interface (BCI) technology.  
  
Tickets are sold out, but we encourage you to watch the livestream by clicking on the link below to learn more about the latest advances in #medtech, #therapeutics, and #neuroscience. Don’t miss our presentation at 11:20 am CET today. 
 
#EmpoweringMovement #SCI #Innovation #BioCapitalEurope
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
https://lnkd.in/gJNc-2qG


“There is no protocol for this. You must figure it out every day...” 
 
Kevin Babington, a former Olympian and equestrian champion with an SCI, and his wife Dianna recently shared a glimpse into their daily lives with our ONWARD team. Kevin had just experienced a medical setback and the resulting emotions were clear in our candid conversation about the struggles for people living with spinal cord injury.
 
Dianna openly shared how their lives have changed since Kevin’s injury during the 2019 Hampton Classic Horse Show. “There is no more cuddling on the couch, no spontaneous trips…it is everyday grinding, even with all the support that we have found within our community.” Dianna’s testimony was gripping and demonstrated a deep vulnerability that both moved and motivated us. 
 
Despite their challenges, Kevin and Dianna are optimistic things will get better and said they are cheering for companies like ONWARD that are dedicated to making new solutions a reality. Read more about the Babington’s work to bring hope to other equestrians with SCI through the The Kevin Babington Foundation.
 
*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
#EmpoweringMovement #SCI

✨ Thanks to De 7, the podcast from Belgian newspaper De Tijd, for its deep dive on brain-computer interface (BCI) technology. The episode, which was in Dutch, examined the buzz behind last week’s news about Neuralink’s first human implant, what it means, and the opportunities for investors. 
 
The show also laid out the events leading up to the news, and noted “this is not a first, the Dutch company ONWARD already implanted one [BCI] several years ago.” 

Education around new scientific breakthroughs is vital to continue progress and prevent misinformation. We appreciate journalists who help the public learn more about this groundbreaking investigational technology that has the potential to be used in combination with our investigational ARC Therapy™ to improve the lives of those with spinal cord injuries or other movement disorders. 

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

#EmpoweringMovement #BCI #SCI

It was a pleasure to participate in the Degroof Petercam Healthcare Conference this month, where our CEO Dave Marver updated attendees on our progress to launch ARC-EX® later this year. 
 
Thank you to all who joined us. You are critical for our mission to provide innovative solutions to restore movement, function, and independence after spinal cord injury (SCI).

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
  
#EmpoweringMovement #SCI #Investors

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	348K -	852K 144.83%	1.31M 53.29%	911K 30.25%	952K 4.50%	1.91M 100.53%	1.37M 28.29%
accumulated other comprehensive income loss							4.49M -
cash and cash equivalents	7.27M -	8.66M 19.12%	15.13M 74.60%	6.38M 57.82%	89.44M 1,301.49%	41.76M 53.31%	29.77M 28.72%
cash and short term investments	7.27M -	8.66M 19.12%	15.13M 74.60%	6.38M 57.82%	89.44M 1,301.49%	61.76M 30.95%	29.77M 51.80%
common stock					3.62M -	3.62M 0%	3.62M 0%
deferred revenue							538K -
deferred revenue non current					1.39M -
deferrred tax liabilities non current			1.45M -	1.34M 7.25%	1.99M 48.25%	670K 66.35%	631K 5.82%
goodwill			1.73M -	1.61M 7.22%	1.70M 5.91%	1.90M 11.75%	1.84M 3.00%
goodwill and intangible assets	46K -	25K 45.65%	7.38M 29,428.00%	6.83M 7.55%	10.03M 46.95%	10.16M 1.29%	9.80M 3.48%
intangible assets		25K -	5.65M 22,500%	5.22M 7.65%	8.33M 59.58%	8.26M 0.85%	7.96M 3.60%
inventory							936K -
long term debt	10.61M -	17.47M 64.58%	33.68M 92.79%	41.88M 24.35%	13.19M 68.50%	13.95M 5.75%	16.31M 16.89%
long term investments
net debt	3.39M -	8.90M 162.56%	18.67M 109.87%	35.63M 90.82%	-75.78M 312.66%	-27.38M 63.86%	-12.89M 52.91%
net receivables							414K -
other assets
other current assets	66K -	92K 39.39%	169K 83.70%	416K 146.15%	2.25M 440.38%	1.17M 47.91%	305K 73.95%
other current liabilities	740K -	1.06M 42.97%	1.28M 21.17%	1.62M 26.13%	4.12M 154.61%	5.88M 42.94%	4.21M 28.55%
other liabilities
other non current assets
other non current liabilities	324K -	356K 9.88%	429K 20.51%	399K 6.99%	1K 99.75%	1.12M 112,000%	2.08M 85.64%
othertotal stockholders equity	5.63M -	9.17M 62.77%	18.00M 96.31%	20.84M 15.79%	155.03M 644.00%	157.33M 1.48%	155.25M 1.32%
preferred stock
property plant equipment net	650K -	539K 17.08%	469K 12.99%	397K 15.35%	2.38M 499.50%	2.10M 11.93%	2.09M 0.19%
retained earnings	-9.52M -	-19.44M 104.07%	-32.92M 69.37%	-52.93M 60.80%	-75.97M 43.53%	-108.32M 42.57%	-145.43M 34.26%
short term debt	49K -	95K 93.88%	126K 32.63%	137K 8.73%	473K 245.26%	427K 9.73%	568K 33.02%
short term investments						20M -
tax assets						163K -	310K 90.18%
tax payables	39K -	111K 184.62%	41K 63.06%	394K 860.98%	209K 46.95%	685K 227.75%	706K 3.07%
total assets	8.18M -	9.56M 16.83%	23.34M 144.19%	14.19M 39.22%	104.80M 638.52%	76.59M 26.91%	43.63M 43.04%
total current assets	7.49M -	9.00M 20.15%	15.49M 72.23%	6.97M 55.03%	92.39M 1,225.88%	64.18M 30.54%	31.42M 51.04%
total current liabilities	1.14M -	2.00M 76.34%	2.71M 35.36%	2.67M 1.81%	5.54M 107.95%	8.22M 48.34%	6.68M 18.74%
total debt	10.66M -	17.56M 64.71%	33.80M 92.47%	42.02M 24.29%	13.66M 67.48%	14.38M 5.21%	16.87M 17.37%
total investments						20M -
total liabilities	12.07M -	19.83M 64.22%	38.27M 92.99%	46.28M 20.95%	22.11M 52.22%	23.96M 8.36%	25.70M 7.24%
total liabilities and stockholders equity	8.18M -	9.56M 16.83%	23.34M 144.19%	14.19M 39.22%	104.80M 638.52%	76.59M 26.91%	43.63M 43.04%
total non current assets	696K -	564K 18.97%	7.85M 1,292.02%	7.22M 8.01%	12.41M 71.82%	12.42M 0.06%	12.21M 1.70%
total non current liabilities	10.94M -	17.82M 62.95%	35.55M 99.47%	43.62M 22.69%	16.57M 62.01%	15.74M 5.01%	19.02M 20.82%
total stockholders equity	-3.89M -	-10.27M 163.85%	-14.92M 45.32%	-32.09M 115.07%	82.68M 357.62%	52.63M 36.35%	17.93M 65.93%

COM:ONWD

Wuhan Donglisheng M&E Technology Co., LTD

Last Close

4.66

22/11 16:35

Market Cap

179.38M

Beta: -

Volume Today

59.94K

Avg: -

Preview